152 related articles for article (PubMed ID: 12814461)
1. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L
Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.
Yue QY; Zhong ZH; Tybring G; Dalén P; Dahl ML; Bertilsson L; Sjöqvist F
Clin Pharmacol Ther; 1998 Oct; 64(4):384-90. PubMed ID: 9797795
[TBL] [Abstract][Full Text] [Related]
3. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
Dalén P; Dahl ML; Eichelbaum M; Bertilsson L; Wilkinson GR
Pharmacogenetics; 1999 Dec; 9(6):697-706. PubMed ID: 10634132
[TBL] [Abstract][Full Text] [Related]
4. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.
Dalén P; Dahl ML; Bernal Ruiz ML; Nordin J; Bertilsson L
Clin Pharmacol Ther; 1998 Apr; 63(4):444-52. PubMed ID: 9585799
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
6. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
7. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
8. Sequence-based CYP2D6 genotyping in the Korean population.
Lee SY; Sohn KM; Ryu JY; Yoon YR; Shin JG; Kim JW
Ther Drug Monit; 2006 Jun; 28(3):382-7. PubMed ID: 16778723
[TBL] [Abstract][Full Text] [Related]
9. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.
Dahl ML; Bertilsson L; Nordin C
Psychopharmacology (Berl); 1996 Feb; 123(4):315-9. PubMed ID: 8867869
[TBL] [Abstract][Full Text] [Related]
10. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.
Weerasuriya K; Jayakody RL; Smith CA; Wolf CR; Tucker GT; Lennard MS
Br J Clin Pharmacol; 1994 Nov; 38(5):466-70. PubMed ID: 7893590
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Modeling Analysis Demonstrates the Impact of CYP2C19 and CYP2D6 Genetic Polymorphisms on the Pharmacokinetics of Amitriptyline and Its Metabolite, Nortriptyline.
Koh A; Pak KC; Choi HY; Ryu S; Choi SE; Kim KS; Bae KS; Lim HS
J Clin Pharmacol; 2019 Apr; 59(4):532-540. PubMed ID: 30452773
[TBL] [Abstract][Full Text] [Related]
12. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients.
Solai LK; Pollock BG; Mulsant BH; Frye RF; Miller MD; Sweet RA; Kirshner M; Sorisio D; Begley A; Reynolds CF
J Clin Psychopharmacol; 2002 Oct; 22(5):481-6. PubMed ID: 12352271
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression.
Murphy GM; Pollock BG; Kirshner MA; Pascoe N; Cheuk W; Mulsant BH; Reynolds CF
Neuropsychopharmacology; 2001 Nov; 25(5):737-43. PubMed ID: 11682257
[TBL] [Abstract][Full Text] [Related]
14. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A
Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230
[TBL] [Abstract][Full Text] [Related]
15. Quantitative pharmacogenetics of nortriptyline: a novel approach.
Kvist EE; Al-Shurbaji A; Dahl ML; Nordin C; Alván G; Ståhle L
Clin Pharmacokinet; 2001; 40(11):869-77. PubMed ID: 11735606
[TBL] [Abstract][Full Text] [Related]
16. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians.
Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF
Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719
[TBL] [Abstract][Full Text] [Related]
17. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
19. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
[TBL] [Abstract][Full Text] [Related]
20. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.
Wennerholm A; Johansson I; Massele AY; Lande M; Alm C; Aden-Abdi Y; Dahl ML; Ingelman-Sundberg M; Bertilsson L; Gustafsson LL
Pharmacogenetics; 1999 Dec; 9(6):707-14. PubMed ID: 10634133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
